MCL1 and B-cell chronic lymphocytic leukemia: ABT‐263 is orally bioavailable and has shown activity in the treatment of chronic lymphocytic leukaemia (CLL) 82, 83; results in solid tumours have been more modest, perhaps reflecting higher levels of, and dependence upon, MCL1 or A1.